Early-stage prostate cancer: When is observation appropriate?

Hematology/Oncology Clinics of North America

Volumn 10, Issue 3, 1996, Pages 611-625

  Albertsen, P C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; EARLY DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; TUMOR VOLUME;

EID: 0030008351     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70356-7     Document Type: Article

References (40)

1. P.C. Albertsen A 72-year old man with localized prostate cancer JAMA 274 1995 69 74
2. P.C. Albertsen Decision Making in Urology. Monographs in Urology 1995 Medical Directions Publishing New Haven 69 82
3. P.C. Albertsen D.G. Fryback B.E. Storer Long term survival among men with conservatively treated prostate cancer JAMA 274 1995 626 631
4. Albertsen P.C. Fryback D.G. Storer B.E. The impact of co-morbidity on life expectancy among men with localized prostate cancer J Urol 1996 in press
5. C.B. Brendler P.C. Walsh The role of radical prostatectomy in the treatment of prostate cancer CA Cancer J Clin 42 1992 212 222
6. B.S. Carter T.H. Beatty G.D. Steinberg Mendelian inheritance of familial prostate cancer Proc Natl Acad Sci USA 89 1992 3367 3371
7. H.B. Carter J.D. Pearson E.J. Metter Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267 1992 2215 2220
8. W.J. Catalona D.S. Smith T.L. Ratliff Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based testing JAMA 270 1993 948 954
9. M.E. Charlson P. Pompei K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation Journal of Chronic Diseases 40 1987 373 383
10. G.W. Chodak R. Thisted G. Gerber Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
11. C. Fleming J.H. Wasson P.C. Albertsen the Prostate Patient Outcomes Research Team A decision analysis of alternative treatment strategies for clinically localized prostate cancer JAMA 269 1993 2650 2658
12. F.J. Fowler M.J. Barry G. Lu-Yao Patient reported complications and follow-up treatment after radical prostatectomy Urology 42 1993 622 629
13. J.F. Gaeta L.C. Englander G.P. Murphy Comparative Evaluation of National Prostatic Cancer Treatment Group and Gleason systems for pathologic grading of primary prostate cancer Urology 27 1986 306 308
14. P.H. Gann C.H. Hennekens M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
15. D.F. Gleason G. Mellinger The Veterans Administration Cooperative Urologic Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging J Urol 111 1974 58 64
16. S. Graham B. Harighey J. Marshall Diet in the epidemiology of prostatic cancer J Natl Cancer Inst 70 1983 687 692
17. S. Greenfield G. Apolone B.J. McNeil The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement Med Care 31 1993 141 154
18. J.E. Johansson H.O. Adami S.O. Andersson High 10-year survival rate in patients with early untreated prostatic cancer JAMA 267 1992 2191 2196
19. M.H. Kaplan A.R. Feinstein The importance of classifying initial co-morbidity in evaluating the outcomes of diabetes mellitus Journal of Chronic Diseases 27 1974 387 404
20. P.H. Lange The next era for prostate cancer: Controlled clinical trials JAMA 269 1993 95 96
21. C.A. Lawton M. Won M.V. Pilepich Long-term sequelae following external beam irradiation for treatment of adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706 Int J Radiat Oncol Biol Phys 21 1991 935 939
22. S.E. Lee S.M. Currin D.F. Paulson Flow cytometric determination of ploidy in prostatic adenocarcinoma. A comparison with seminal vesicle involvement and histopathologic grading as a predictor of clinical recurrence J Urol 140 1988 769
23. G.L. Lu-Yao A.L. Potosky P.C. Albertsen Follow-up prostate cancer treatments after radical prostatectomy: A population-based study J Natl Cancer Inst 88 1996 166 173
24. H. Mameghan R. Fisher W.H. Watt Results of radiotherapy for localized prostatic carcinoma treated at the Prince of Wales Hospital, Sydney Med J Aust 154 1991 317 326
25. J.E. McNeal D.G. Bostwick R.A. Kindrachuk Patterns of progression in prostate cancer Lancet 1 1986 60 63
26. C. Mettlin G.W. Jones G.P. Murphy Trends in prostate cancer care in the United States, 1974-1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer CA Cancer J Clin 43 1993 83 91
27. J.E. Oesterling S.J. Jacobsen C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men JAMA 270 1993 860 864
28. A.W. Partin J. Yoo H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer J Urol 150 1993 110 114
29. A.L. Potosky B.A. Miller P.C. Albertsen The role of increasing detection in the rising incidence of prostate cancer JAMA 273 1995 548 552
30. P.T. Scardino Early detection of prostate cancer Urol Clin North Am 16 1989 635 655
31. H.P. Schmid J.E. McNeal T.A. Stamey Observations on the doubling time of prostate 625 cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume Cancer 71 1993 2031 2040
32. H. Seidman M.H. Mushinski S.K. Gelb Probabilities of eventually developing or dying of cancer CA Cancer J Clin 35 1985 36 56
33. W.U. Shipley A.L. Zietman G.E. Hanks Treatment related sequelae following external beam radiation for prostate cancer: A review with an update in patients with stages T1 and T2 tumor J Urol 152 1994 1799 1805
34. J. Song W.S. Cheng R.E. Cupps Nuclear deoxyribonucleic acid content measured by static cytometry: Important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy J Urol (part 2) 147 1992 794
35. T.A. Stamey Making the most out of six systematic sextant biopsies Urology 45 1995 2 12
36. T.A. Stamey F.S. Freiha J.E. McNeil Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 1993 933 938
37. T.A. Stamey N. Yang A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916
38. R.A. Stephenson B.C. James H. Gay Flow cytometry of prostate cancer: Relationship of DNA content to survival Cancer Res 47 1987 2504
39. J. Wasson C.C. Cushman R.B. Bruskewitz A structured literature review of treatment for localized prostate cancer Arch Fam Med 2 1993 487 493
40. P.A. Wingo T. Tong S. Bolden Cancer Statistics, 1995 CA Cancer J Clin 45 1995 8 30